VERAXA Biotech (NASDAQ: VRXA) is developing antibody-based cancer therapies designed to improve treatment selectivity and potentially reduce toxicity to healthy tissues, according to a recent BioMedNewsBreaks announcement. At the core of the company's strategy is its proprietary Bi-targeted Tumor-Associated Cytotoxicity (BiTAC) platform, which uses two complementary molecules engineered to activate cancer-killing activity only when both recognize targets on the same tumor cell. This dual-targeting requirement could offer a safety advantage over conventional therapies that may inadvertently affect healthy cells.
The company is applying the BiTAC approach to antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), with a particular focus on solid tumors. VERAXA reported promising preclinical findings for its lead BiTAC-TCE program, including selective targeting of cells expressing both intended targets and improved safety alongside comparable efficacy to a conventional TCE in animal studies. These results suggest that the BiTAC platform could potentially deliver more precise tumor targeting while maintaining therapeutic effectiveness.
In addition to its TCE work, VERAXA is developing complementary ADC technologies, including site-specific conjugation and tumor-selective payload-linker systems, in markets experiencing substantial projected growth. The company's integrated approach across multiple antibody formats positions it to address a range of cancer types with potentially safer and more effective treatments.
The implications of this announcement are significant for the oncology field. By requiring dual target recognition, BiTAC therapies could reduce off-tumor toxicity, a common challenge in cancer treatment, and potentially improve patient outcomes. VERAXA's progress in preclinical studies, particularly the selective targeting observed in its lead program, underscores the potential of its platform to advance into clinical development. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research. For regular updates about VERAXA Biotech, visit https://investors.veraxa.com. The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA.
BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, published the announcement. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire, editorial syndication to over 5,000 outlets, and other services. For more information, visit BioMedWire.
